FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309614213> ?p ?o ?g. }

• W4309614213 endingPage "5627" @default.
• W4309614213 startingPage "5627" @default.
• W4309614213 abstract "Despite advances in clinical management, osteosarcoma and Ewing sarcoma, the two most frequent malignant primary bone tumors at pediatric age, still have a poor prognosis for high-risk patients (i.e., relapsed or metastatic disease). Triggering a TRAIL pro-apoptotic pathway represents a promising therapeutic approach, but previous studies have described resistance mechanisms that could explain the declining interest of such an approach in clinical trials. In this study, eight relevant human cell lines were used to represent the heterogeneity of the response to the TRAIL pro-apoptotic effect in pediatric bone tumors and two cell-derived xenograft models were developed, originating from a sensitive and a resistant cell line. The DR5 agonist antibody AMG655 (Conatumumab) was selected as an example of TRAIL-based therapy. In both TRAIL-sensitive and TRAIL-resistant cell lines, two signaling pathways were activated following AMG655 treatment, the canonical extrinsic apoptotic pathway and a non-apoptotic pathway, involving the recruitment of RIPK1 on the DR5 protein complex, activating both pro-survival and pro-proliferative effectors. However, the resulting balance of these two pathways was different, leading to apoptosis only in sensitive cells. In vivo, AMG655 treatment reduced tumor development of the sensitive model but accelerated tumor growth of the resistant one. We proposed two independent strategies to overcome this issue: (1) a proof-of-concept targeting of RIPK1 by shRNA approach and (2) the use of a novel highly-potent TRAIL-receptor agonist; both shifting the balance in favor of apoptosis. These observations are paving the way to resurrect TRAIL-based therapies in pediatric bone tumors to help predict the response to treatment, and propose a relevant adjuvant strategy for future therapeutic development." @default.
• W4309614213 created "2022-11-28" @default.
• W4309614213 creator A5041397345 @default.
• W4309614213 creator A5043002838 @default.
• W4309614213 creator A5046241990 @default.
• W4309614213 creator A5047752765 @default.
• W4309614213 creator A5049291969 @default.
• W4309614213 creator A5061517866 @default.
• W4309614213 creator A5075730887 @default.
• W4309614213 creator A5076062251 @default.
• W4309614213 date "2022-11-16" @default.
• W4309614213 modified "2023-10-01" @default.
• W4309614213 title "TRAIL-Based Therapies Efficacy in Pediatric Bone Tumors Models Is Modulated by TRAIL Non-Apoptotic Pathway Activation via RIPK1 Recruitment" @default.
• W4309614213 cites W1539052865 @default.
• W4309614213 cites W1560585642 @default.
• W4309614213 cites W1585505607 @default.
• W4309614213 cites W1966150411 @default.
• W4309614213 cites W1971895570 @default.
• W4309614213 cites W1980088710 @default.
• W4309614213 cites W1980919524 @default.
• W4309614213 cites W1984054570 @default.
• W4309614213 cites W1984554785 @default.
• W4309614213 cites W1994269886 @default.
• W4309614213 cites W1996840415 @default.
• W4309614213 cites W1999941834 @default.
• W4309614213 cites W2003014847 @default.
• W4309614213 cites W2016883314 @default.
• W4309614213 cites W2017932620 @default.
• W4309614213 cites W2042936828 @default.
• W4309614213 cites W2061116212 @default.
• W4309614213 cites W2077413589 @default.
• W4309614213 cites W2079317833 @default.
• W4309614213 cites W2086665516 @default.
• W4309614213 cites W2087590198 @default.
• W4309614213 cites W2089521856 @default.
• W4309614213 cites W2091520604 @default.
• W4309614213 cites W2121580023 @default.
• W4309614213 cites W2123104430 @default.
• W4309614213 cites W2131357993 @default.
• W4309614213 cites W2132067615 @default.
• W4309614213 cites W2144824249 @default.
• W4309614213 cites W2158662692 @default.
• W4309614213 cites W2166566481 @default.
• W4309614213 cites W2167955987 @default.
• W4309614213 cites W2170434175 @default.
• W4309614213 cites W2321395951 @default.
• W4309614213 cites W2509589535 @default.
• W4309614213 cites W2620490360 @default.
• W4309614213 cites W2769354967 @default.
• W4309614213 cites W2795113333 @default.
• W4309614213 cites W2799281825 @default.
• W4309614213 cites W2887977895 @default.
• W4309614213 cites W2947419359 @default.
• W4309614213 cites W2966997586 @default.
• W4309614213 cites W3013646757 @default.
• W4309614213 cites W3035434204 @default.
• W4309614213 cites W3193460200 @default.
• W4309614213 cites W4211227438 @default.
• W4309614213 cites W4225981818 @default.
• W4309614213 cites W4285719527 @default.
• W4309614213 doi "https://doi.org/10.3390/cancers14225627" @default.
• W4309614213 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36428719" @default.
• W4309614213 hasPublicationYear "2022" @default.
• W4309614213 type Work @default.
• W4309614213 citedByCount "0" @default.
• W4309614213 crossrefType "journal-article" @default.
• W4309614213 hasAuthorship W4309614213A5041397345 @default.
• W4309614213 hasAuthorship W4309614213A5043002838 @default.
• W4309614213 hasAuthorship W4309614213A5046241990 @default.
• W4309614213 hasAuthorship W4309614213A5047752765 @default.
• W4309614213 hasAuthorship W4309614213A5049291969 @default.
• W4309614213 hasAuthorship W4309614213A5061517866 @default.
• W4309614213 hasAuthorship W4309614213A5075730887 @default.
• W4309614213 hasAuthorship W4309614213A5076062251 @default.
• W4309614213 hasBestOaLocation W43096142131 @default.
• W4309614213 hasConcept C126322002 @default.
• W4309614213 hasConcept C142724271 @default.
• W4309614213 hasConcept C150903083 @default.
• W4309614213 hasConcept C170493617 @default.
• W4309614213 hasConcept C190283241 @default.
• W4309614213 hasConcept C207001950 @default.
• W4309614213 hasConcept C2777760704 @default.
• W4309614213 hasConcept C2778256501 @default.
• W4309614213 hasConcept C2778938600 @default.
• W4309614213 hasConcept C502942594 @default.
• W4309614213 hasConcept C55493867 @default.
• W4309614213 hasConcept C62478195 @default.
• W4309614213 hasConcept C71924100 @default.
• W4309614213 hasConcept C86803240 @default.
• W4309614213 hasConcept C95444343 @default.
• W4309614213 hasConceptScore W4309614213C126322002 @default.
• W4309614213 hasConceptScore W4309614213C142724271 @default.
• W4309614213 hasConceptScore W4309614213C150903083 @default.
• W4309614213 hasConceptScore W4309614213C170493617 @default.
• W4309614213 hasConceptScore W4309614213C190283241 @default.
• W4309614213 hasConceptScore W4309614213C207001950 @default.
• W4309614213 hasConceptScore W4309614213C2777760704 @default.
• W4309614213 hasConceptScore W4309614213C2778256501 @default.

• next